ASLAN Pharmaceuticals Limited (ASLN)
NASDAQ: ASLN · IEX Real-Time Price · USD
0.600
-0.100 (-14.27%)
At close: Jul 18, 2024, 4:00 PM
0.560
-0.040 (-6.67%)
After-hours: Jul 18, 2024, 7:58 PM EDT
ASLAN Pharmaceuticals Employees
ASLAN Pharmaceuticals had 35 employees as of December 31, 2023. The number of employees increased by 1 or 2.94% compared to the previous year.
Employees
35
Change (1Y)
1
Growth (1Y)
2.94%
Revenue / Employee
$342,857
Profits / Employee
-$1,000,765
Market Cap
2.69M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 35 | 1 | 2.94% |
| Dec 31, 2022 | 34 | 7 | 25.93% |
| Dec 31, 2021 | 27 | 9 | 50.00% |
| Dec 31, 2020 | 18 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TC Biopharm (Holdings) | 41 |
| INVO Bioscience | 30 |
| FOXO Technologies | 29 |
| Helius Medical Technologies | 22 |
| Virax Biolabs Group | 11 |
| Altamira Therapeutics | 10 |
| Entero Therapeutics | 9 |
| Alzamend Neuro | 7 |
ASLN News
- 4 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 5 days ago - ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation - GlobeNewsWire
- 7 days ago - ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - GlobeNewsWire
- 2 months ago - ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference - GlobeNewsWire
- 2 months ago - ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event - GlobeNewsWire
- 2 months ago - ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics - GlobeNewsWire
- 2 months ago - ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab - GlobeNewsWire